Healthcare provider profile · identity verified

Mary E Fairbanks, MD

Family Practice · DENVER, CO · NPI 1457360406

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	178	53
Atorvastatin Calcium	Atorvastatin Calcium	140	52
Losartan Potassium	Losartan Potassium	125	39
Lisinopril	Lisinopril	115	38
Levothyroxine Sodium	Levothyroxine Sodium	114	39
Gabapentin	Gabapentin	102	32
Ibuprofen	Ibuprofen	72	27
Albuterol Sulfate Hfa	Albuterol Sulfate	68	26
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	68	17
Metformin Hcl Er	Metformin Hcl	67	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	57	11
Metoprolol Succinate	Metoprolol Succinate	57	17
Duloxetine Hcl	Duloxetine Hcl	55	16
Pravastatin Sodium	Pravastatin Sodium	54	16
Alprazolam	Alprazolam	53	12
Metformin Hcl	Metformin Hcl	46	19
Tramadol Hcl	Tramadol Hcl	45	11
Omeprazole	Omeprazole	43	16
Famotidine	Famotidine	40	15
Hydrochlorothiazide	Hydrochlorothiazide	40	13
Bupropion Xl	Bupropion Hcl	37	16
Escitalopram Oxalate	Escitalopram Oxalate	36	11
Tizanidine Hcl	Tizanidine Hcl	35	suppressed
Atenolol	Atenolol	34	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	34	14
Trazodone Hcl	Trazodone Hcl	34	suppressed
Nabumetone	Nabumetone	32	11
Tamsulosin Hcl	Tamsulosin Hcl	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	22
Advair Hfa	Fluticasone Propion/Salmeterol	29	suppressed
Simvastatin	Simvastatin	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	28	12
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Oxycodone Hcl	Oxycodone Hcl	27	suppressed
Trulicity	Dulaglutide	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	11
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Cephalexin	Cephalexin	22	17
Eliquis	Apixaban	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Naproxen	Naproxen	22	suppressed
Fluconazole	Fluconazole	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Diazepam	Diazepam	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Glipizide	Glipizide	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Azithromycin	Azithromycin	18	18
Potassium Chloride	Potassium Chloride	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Sucralfate	Sucralfate	17	suppressed
Carvedilol	Carvedilol	16	suppressed
Furosemide	Furosemide	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	15	12
Allopurinol	Allopurinol	14	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	14	14
Celecoxib	Celecoxib	14	suppressed
Nystatin	Nystatin	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Baclofen	Baclofen	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Ozempic	Semaglutide	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Victoza 2-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error